Parker Waichman LLP Headlines by Topic
Risperdal
Feds Say Kickbacks Paid to Increase use of Risperdal, Levaquin at Omnicare Nursing Home Change
Jan 18, 2010
| Parker Waichman LLP
Johnson & Johnson has been charged with paying kickbacks to the Omnicare nursing home chain in order to increase the use of its drugs at the...
Atypical Antipsychotics Linked to Worrisome Weight Gains, Other Outcomes, in Children
Oct 28, 2009
| Parker Waichman LLP
Yet another study has linked significant weight gains in children to some antipsychotic medication. Forbes reported that an emerging study found that...
Risperdal Said to be Responsible for Breast Growth in Boys
Jun 25, 2009
| Parker Waichman LLP
Risperdal has been linked to breast growth, and even lactation, in boys under 18 who take the powerful antipsychotic drug. The condition is...
Risperdal Researcher Promised Drug Maker Positive Results from Clinical Trials
Mar 20, 2009
| Parker Waichman LLP
A prominent Harvard psychiatrist promised positive results to Johnson & Johnson before the start of some clinical trials for Risperdal. ...
Misleading Risperdal, Duragesic Patch Claims Prompt Fines in West Virginia Lawsuit
Mar 4, 2009
| Parker Waichman LLP
Risperdal maker Johnson & Johnson has been ordered by a West Virginia judge to pay a hefty fine over a 2003 letter to doctors that obfuscated the...
Atypical Antipsychotic Drugs Double Heart Risks
Jan 15, 2009
| Parker Waichman LLP, LLP
Atypical antipsychotic drugs, including Seroquel, Zyprexa and Risperdal, double the risk of heart failure and death, according to a new study...
Alzheimer's Patients on Risperdal, Thorazine, Other Anti-Psychotic Drugs, More Likely to Die
Jan 9, 2009
| Parker Waichman LLP
Using anti-psychotic drugs, such as Risperdal and Thorazine, to treat Alzheimer's disease patients isn't worth the increased risk of death, a new...
Doctor Agrees to Cut Drug Firm Ties
Jan 5, 2009
| Parker Waichman LLP
Dr. Joseph Biederman is the latest doctor whose activities with big pharmaceutical are under review. According to the Boston Globe’s...
Risperdal Promotion Questioned in Lawsuit
Nov 25, 2008
| Parker Waichman LLP
A prominent Harvard psychiatrist may have promised that his work at a psychiatric research institute would promote the off-label pediatric use...
Panel Questions Antipsychotics for Kids
Nov 20, 2008
| Parker Waichman LLP
Reuters is reporting that a panel of external experts is urging the U.S. Food and Drug Administration (FDA) and “other U.S. health...
